ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2021
Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Distinct sex-specific DNA methylation differences in Alzheimer's disease.Alzheimer's research & therapy · 2022Pooled it
- Pharmacogenomics testing to optimize medical countermeasures against chemical warfare agents and bacterial biothreats in military settings.Journal of military, veteran and family health · 2026Article
- Nationwide trends in psychiatric prescription practices for drugs with putative cognitive adverse effects in schizophrenia spectrum and bipolar disorders from 2013 to 2022.Journal of pharmaceutical policy and practice · 2026Article
- Association Analysis of Inter-Alpha-Trypsin Inhibitor Genes in Schizophrenia.Juntendo medical journal · 2026Article
- Investigation of Genetic Changes in Three Families with Bipolar Disease.Molecular syndromology · 2024Article
- Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives.Brain sciences · 2024Review
- Identifying novel proteins for migraine by integrating proteomes from blood and CSF with genome-wide association data.CNS neuroscience & therapeutics · 2024Article
- Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.Schizophrenia bulletin open · 2024Article
- Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.Frontiers in psychiatry · 2024Review
- The genetic relationships between brain structure and schizophrenia.Nature communications · 2023Article
- De novo network analysis reveals autism causal genes and developmental links to co-occurring traits.Life science alliance · 2023Article
- Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders.Schizophrenia research · 2023Article
- Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system.Translational psychiatry · 2023Review
- European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Review
- Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.Schizophrenia research. Cognition · 2022Review
- Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study.Schizophrenia research · 2022Article
- Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.Frontiers in psychiatry · 2022Review
- Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes.Frontiers in genetics · 2022Article
- Cognitive deficits in familial schizophrenia.Industrial psychiatry journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 14 institutions in 2 countries.
Funding
Abstract
Identifying genetic contributors to cognitive impairments in psychosis-spectrum disorders can advance understanding of disease pathophysiology. Although CNS medications are known to affect cognitive performance, they are often not accounted for in genetic association studies. In this study, we performed a genome-wide association study (GWAS) of global cognitive performance, measured as composite z-scores from the Brief Assessment of Cognition in Schizophrenia (BACS), in persons with psychotic disorders and controls (N = 817; 682 cases and 135 controls) from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Analyses accounting for anticholinergic exposures from both psychiatric and non-psychiatric medications revealed five significantly associated variants located at the chromosome 3p21.1 locus, with the top SNP rs1076425 in the inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) gene (P = 3.25×E-9). The inclusion of anticholinergic burden improved association models (P < 0.001) and the number of significant SNPs identified. The effect sizes and direction of effect of the top variants remained consistent when investigating findings within individuals receiving specific antipsychotic drugs and after accounting for antipsychotic dose. These associations were replicated in a separate study sample of untreated first-episode psychosis. The chromosome 3p21.1 locus was previously reported to have association with the risk for psychotic disorders and cognitive performance in healthy individuals. Our findings suggest that this region may be a psychosis risk locus that is associated with cognitive mechanisms. Our data highlight the general point that the inclusion of medication exposure information may improve the detection of gene-cognition associations in psychiatric genetic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.